The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease.

[1]  M. Regueiro,et al.  Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  Trevor Murrells,et al.  Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings , 2014, Gut.

[3]  E. Savarino,et al.  Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial , 2013, The American Journal of Gastroenterology.

[4]  David A W Soergel,et al.  Association of gut microbiota with post-operative clinical course in Crohn’s disease , 2013, BMC Gastroenterology.

[5]  J. Galmiche,et al.  Saccharomyces boulardii does not prevent relapse of Crohn's disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  A. Andoh,et al.  Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease , 2013, Journal of gastroenterology and hepatology.

[7]  R. Ploeg,et al.  Prevention of postoperative recurrence of Crohn's disease. , 2012, Journal of Crohn's & colitis.

[8]  A. Gasbarrini,et al.  Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study , 2010, The American Journal of Gastroenterology.

[9]  A. Sood,et al.  The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  R. Baldassano,et al.  Effect of a Probiotic Preparation (VSL#3) on Induction and Maintenance of Remission in Children With Ulcerative Colitis , 2009, The American Journal of Gastroenterology.

[11]  G. Cabibbo,et al.  Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. , 2008, Gastroenterology.

[12]  J. Doré,et al.  Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients , 2008, Proceedings of the National Academy of Sciences.

[13]  Judy H. Cho,et al.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.

[14]  Alastair Forbes,et al.  Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease , 2008, Nature Genetics.

[15]  D. Marks,et al.  Innate immunity in inflammatory bowel disease: a disease hypothesis , 2008, The Journal of pathology.

[16]  K. Whelan,et al.  Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials , 2007, Proceedings of the Nutrition Society.

[17]  O. Dewit,et al.  Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo‐caecal resection , 2007 .

[18]  Z. Halpern,et al.  Failure of Synbiotic 2000 to Prevent Postoperative Recurrence of Crohn’s Disease , 2007, Digestive Diseases and Sciences.

[19]  J. Mary,et al.  Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial , 2005, Gut.

[20]  R. Bibiloni,et al.  VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis , 2005, The American Journal of Gastroenterology.

[21]  A. Tursi,et al.  Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[22]  C. Prantera,et al.  Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG , 2002, Gut.

[23]  C. De Simone,et al.  Probiotic bacteria enhance murine and human intestinal epithelial barrier function. , 2001, Gastroenterology.

[24]  A. Forbes,et al.  Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease , 2001, Gut.

[25]  P. Brigidi,et al.  Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial , 2000, Gastroenterology.

[26]  F. Rizzello,et al.  Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: A randomized controlled study VS mesalamine , 2000 .

[27]  D. Matteuzzi,et al.  Traditional and High Potency Probiotic Preparations for Oral Bacteriotherapy , 1999, BioDrugs.

[28]  M. Adams.  Safety of industrial lactic acid bacteria. , 1999, Journal of biotechnology.

[29]  P. Rutgeerts,et al.  Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. , 1995, Gastroenterology.

[30]  P. Rutgeerts.  Recurrence of Crohn's disease in the neoterminal ileum after ileal resection: is prevention therapy possible? , 1994, The Netherlands journal of medicine.

[31]  P. Rutgeerts,et al.  Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.

[32]  B. Vaughn,et al.  TOPIC HIGHLIGHT , 2014 .